References

• • Profiling muscle transcriptome in mice exposed to microgravity using gene set enrichment analysis. 2025
  • A microfluidic fluidized bed to capture, amplify and detect bacteria from raw samples. Methods in Cell Biology. 2018
  • A new microfluidic approach for the one-step capture, amplification and label-free quantification of bacteria from raw samples. Chemical Science. 2016
  • Rapid screening for specific glycosylation and pathogen interactions on a 78 species avian egg white glycoprotein microarray. Nature Scientific Reports. 2017
  • Exploitation of Glycobiology in Anti-Adhesion Approaches against Biothreat Agents. Journal of Bioterrorism & Biodefense. 2016
  • Assessing Bacterial Interactions Using Carbohydrate-Based Microarrays. MDPI Microarrays. 2015

• Aquila Bioscience collaborates with European Space Agency.
• Muscle atrophy in microgravity environment and multi-omic data analysis.
• Local medtech company develops mask spray which blocks 99 per cent of pathogens. Galway Advertiser.
• Galway medtech develops mask spray to block 99% of pathogens by Lisa Ardill. Siliconrepublic.
• Irish Innovation in Wipes and Masks Could Help Battle Emerging Coronavirus Crisis. NUI Galway Marketing & Communications Office.
• Aquila Bioscience has developed a ground-breaking new barrier spray making re-usable masks up to 99% effective at blocking airborne pathogens and particles. Marketing & Communications Office.
• Innovation is key in battle against Covid-19 by Sylvia Thompson. Irish Times.
• Irish Company Develop Technology Proven to Remove 99.99% of Coronavirus from Human Skin. Marketing & Communications Office.
• Aquila Bioscience is selected for EIC Accelerator Funding. European Commission.
• An emerging Irish technology may be key to containing the Wuhan coronavirus. GRIPT.
• Higher Education Research Activity in response to SARS-CoV-2: Higher Education Research Activity in response to SARS-CoV-2 by Maura O’Shea. HEA Newsletter.

FDA Registration: Aquila Bioscience have been successfully registered as a foreign manufacturing facility for the ABD Device with the FDA under Owner/ Operator Number 10074735

NeoVirTech: French Laboratory of expertise has proven the efficiency of the ABD Device in its ability to capture and remove up to 99.99% of SARS CoV-2 from the human skin.

International Patent Application WIPO 2020/240027 A1. Device and method for decontamination / disinfection.

• 01/2025-06/2026, European Space Agency, Development and validation of protein-carbohydrate based pathogen capture technology (PCT) for biological decontamination suitable for space flights (€175,000).
• 07-2020-01/2023, EIC Accelerator (H2020-EIC-SMEInst-2018-2020-3), COVID-19 pandemic: An innovative, safe and effective bio-decontamination technology for non-toxic removal of biological agents, including coronavirus (Grant agreement ID: 959436), EU contribution: €1,941k (Overall budget: €2,773k)
• 04/2017-04/2021, ITN PathSense (Pathogen Sensing), ABL cost: none/student secondments
• 01/2018 – 06/2018, Glyco-DeCon Feasibility Study (SMEInst-13-2016-2017 Phase I) to verify financial feasibility and review the Intellectual property landscape, EU H2020 SMEInst ABL cost: €71k (total cost €71k)
• 04/2015 – 04/2017, DCLAW: Decontamination by Carbohydrate Lectin Affinity Wipes European Defence Agency, ABL cost: €132k (total cost €248k)
• 05/2014 – 04/2017, NAPES: Next Generation Analytical Platforms for Environmental Sensing, EU FP7-NMP, ABL cost: €480k (total cost €4,539k)